Dollar Tree shares have experienced notable turbulence, with a sharp weekly drop contrasting a strong yearly performance. This analysis delves into the conflicting valuation signals and the macroeconomic pressures shaping the discount retailer's investment narrative.
Divergent analyst reports from Truist and Goldman Sachs on CCC Intelligent Solutions have cast a spotlight on the data firm's path to profitability, revealing deep-seated debates about its role in the auto insurance ecosystem and its ability to convert steady growth into sustained margins.
Electro Optic Systems (EOS), the Australian firm behind a landmark high-energy laser contract, is planning a strategic move of its headquarters and listing to Europe within the year, its CEO reveals, aiming to embed itself at the heart of the continent's urgent defence modernisation drive.
As the Bank of Canada holds rates steady, speculative capital is sifting through junior resource stocks. We examine three micro-caps—a driller, an explorer, and an oil hopeful—navigating unique challenges and opportunities in early 2026.
Alphabet's stock surge, driven by its successful integration of AI, has investors weighing whether its current valuation still offers a compelling entry point for long-term growth.
American Express reported a 10.6% year-over-year revenue increase to $17.57 billion for the fourth quarter of 2025, yet missed Wall Street's sales expectations. Earnings per share of $3.53 met analyst consensus estimates.
Meta Platforms is charting an unprecedented course in capital investment, with plans to spend up to $135 billion by 2026 to build the infrastructure for AI 'superintelligence.' The staggering sum highlights the scale of Big Tech's arms race and raises questions about long-term returns.
A wave of insider selling at AutoZone over the past year, totaling $15 million, has drawn investor scrutiny. While the transactions occurred near current share prices, the scale of divestment compared to minimal buying prompts a closer look at the auto parts retailer's prospects.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank is seen as a pivotal test of its political independence, potentially aligning monetary policy more closely with White House objectives.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
A campaign-trail proposal to temporarily cap credit card interest at 10% could offer significant savings for millions of borrowers, but experts warn of potential unintended consequences for credit access and long-term financial health.
In its Q4 2025 letter, David Einhorn's Greenlight Capital revealed a new position in Antero Resources (AR), signaling a strategic move into the natural gas sector. The hedge fund's portfolio returned 8.5% for the quarter, outpacing the S&P 500.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and advocate for central bank reform, to chair the Fed, following his sustained public criticism of Jerome Powell's interest rate policy.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Despite reporting earnings that edged past expectations, Houlihan Lokey's shares fell 12% post-earnings. Analysts' long-term forecasts remain largely unchanged, signaling a 'steady-as-she-goes' assessment of the investment bank's prospects.
Former Federal Reserve Governor Kevin Warsh, known for his hawkish stance but recently aligned with Trump's calls for lower rates, has been nominated by the former president to chair the Fed. The move, if confirmed, could test the institution's independence amid political pressure and an ongoing Justice Department probe.
SoFi Technologies smashed Wall Street's Q4 2025 revenue and profit forecasts, sending its shares sharply higher. However, the digital finance leader's shockingly weak sales outlook for the coming quarter has injected significant uncertainty into its growth narrative.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
SoundHound AI expands its deployment of voice AI ordering technology with burger chain Five Guys, following a successful pilot handling over a million customer interactions, aiming to enhance service speed and accuracy during peak hours.
